Table 3.

Analysis of posttransplant risk factors for the development of TA-TMA

VariablesUnivariateMultivariate
HR (95% CI)PHR (95% CI)P
Grade 3-4 aGVHD     
 N Reference  Reference  
 Y 4.62 (2.98-7.14) <.01* 4.02 (2.36-6.83) <.01* 
Bacterial infection     
 N Reference    
 Y 1.1 (0.81-1.74) .37   
Aspergillus infection     
 N Reference  Reference  
 Y 2.41 (1.32-4.39) <.01* 2.29 (1.15-4.54) .01* 
Candida infection     
 N Reference    
 Y 1.36 (0.43-4.30) .60   
CMV infection     
 N Reference    
 Y 1.57 (0.64-3.76) .32   
CMV reactivation     
 N Reference  Reference  
 Y 2.01 (1.31-3.09) <.01* 1.51 (0.92-2.47) .09 
Hemorrhagic cystitis     
 N Reference  Reference  
 Y 1.91 (1.00-3.64) .05 1.45 (0.69-3.07) .32 
VOD/SOS     
 N Reference  Reference  
 Y 6.39 (3.66-11.1) <.01* 4.47 (2.25-8.87) <.01* 
VariablesUnivariateMultivariate
HR (95% CI)PHR (95% CI)P
Grade 3-4 aGVHD     
 N Reference  Reference  
 Y 4.62 (2.98-7.14) <.01* 4.02 (2.36-6.83) <.01* 
Bacterial infection     
 N Reference    
 Y 1.1 (0.81-1.74) .37   
Aspergillus infection     
 N Reference  Reference  
 Y 2.41 (1.32-4.39) <.01* 2.29 (1.15-4.54) .01* 
Candida infection     
 N Reference    
 Y 1.36 (0.43-4.30) .60   
CMV infection     
 N Reference    
 Y 1.57 (0.64-3.76) .32   
CMV reactivation     
 N Reference  Reference  
 Y 2.01 (1.31-3.09) <.01* 1.51 (0.92-2.47) .09 
Hemorrhagic cystitis     
 N Reference  Reference  
 Y 1.91 (1.00-3.64) .05 1.45 (0.69-3.07) .32 
VOD/SOS     
 N Reference  Reference  
 Y 6.39 (3.66-11.1) <.01* 4.47 (2.25-8.87) <.01* 

Multivariate analysis was performed including significant pre-HSCT factors (age, PS, HCT-CI, donor source, and HLA mismatch).

*

Statistically significant.

or Create an Account

Close Modal
Close Modal